Myeloproliferative neoplasms (MPNs) are a leading cause of splanchnic vein thrombosis
(SVT). SVT is observed in all MPNs and frequently affects young patients. Therapy should …

Prefibrotic myelofibrosis (pre-PMF) is a distinct entity among chronic myeloproliferative
neoplasm diagnosed according to the revised 2016 WHO classification. The clinical picture …

We collected 1500 patients with myeloproliferative neoplasms (MPN) and arterial or venous
thrombosis (935/565), pooling three independent cohorts previously reported. Long-term …

In myeloproliferative neoplasms (MPNs) the incidence of venous thromboembolism (VTE) is
0.6–1.0 per 100 pt-years, and the rate of recurrence after VTE is 6.0–6.5 per 100 pt-yrs …

Polycythemia vera is characterized by the acquisition of the JAK2V617F mutation.
Recommended treatments include hydroxyurea and interferon-alpha. Several groups have …

Myeloproliferative neoplasms (MPNs) include essential thrombocythemia, polycythemia
vera (PV), and primary myelofibrosis (MF). Phenotype-driver mutations of JAK2, CALR, and …

Refractoriness to ruxolitinib in patients with myelofibrosis (MF) was associated with clonal
evolution; however, whether genetic instability is promoted by ruxolitinib remains unsettled …

Summary The 2016 World Health Organization (WHO) classification for myeloproliferative
neoplasms (MPN) divided myelofibrosis (MF) into pre‐fibrotic (pre‐MF) and overt‐MF …

Clonal proliferation of hematopoietic precursors leading to progressive expansion of
myeloid cells with a predominant increase of red cells characterizes the hematological …

Abstract Purpose of Review The purpose of this review is to help doctors in the management
of patients with post-polycythemia (PPV) and post-essential thrombocythemia (PET) …